Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma

Figure 1 Flow chart of searching strategy for study inclusion. RFA: Radiofrequency ablation; TACE: Transcatheter arterial chemoembolization.

Figure 2 Comparison of combination of radiofrequency ablation and transcatheter arterial chemoembolization with radiofrequency ablation alone for hepatocellular carcinoma in terms of overall survival rates (A-D) and recurrence-free survival rates (E-G). A, E: Meta-analysis of 1-year results; B: Meta-analysis of 2-year results; C, F: Meta-analysis of 3-year results; D, G: Meta-analysis of 5-year results. RFA: Radiofrequency ablation; TACE: Transcatheter arterial chemoembolization; OR: Odds ratio.

Figure 3 Comparison of combination of radiofrequency ablation and transcatheter arterial chemoembolization with radiofrequency ablation alone for hepatocellular carcinoma in terms of tumor progression rate (A) and major complications (B). RFA: Radiofrequency ablation; TACE: Transcatheter arterial chemoembolization; OR: Odds ratio.

Figure 4 Comparison of combination of radiofrequency ablation and transcatheter arterial chemoembolization with radiofrequency ablation alone for small hepatocellular carcinoma in terms of survival rates. A, B: Tumor size ≤ 3 cm; C-F: 3 cm < tumor size ≤ 5 cm; G, H: Tumor size > 5 cm; A, C, F: Meta-analysis of 1-year results; B, D, G: Meta-analysis of 3-year results; E: Meta-analysis of 5-year results.

Figure 5 Funnel plot in the analysis of the effect of 1-year overall survival rate. OR: Odds ratio.